Current challenges and future opportunities of phage therapy.
One-Health
clinical trials
phage cocktails
phage engineering
phage resistance
regulatory framework
Journal
FEMS microbiology reviews
ISSN: 1574-6976
Titre abrégé: FEMS Microbiol Rev
Pays: England
ID NLM: 8902526
Informations de publication
Date de publication:
24 11 2020
24 11 2020
Historique:
received:
23
03
2020
accepted:
29
05
2020
pubmed:
31
5
2020
medline:
9
3
2021
entrez:
31
5
2020
Statut:
ppublish
Résumé
Antibiotic resistance is a major public health challenge worldwide, whose implications for global health might be devastating if novel antibacterial strategies are not quickly developed. As natural predators of bacteria, (bacterio)phages may play an essential role in escaping such a dreadful future. The rising problem of antibiotic resistance has revived the interest in phage therapy and important developments have been achieved over the last years. But where do we stand today and what can we expect from phage therapy in the future? This is the question we set to answer in this review. Here, we scour the outcomes of human phage therapy clinical trials and case reports, and address the major barriers that stand in the way of using phages in clinical settings. We particularly address the potential of phage resistance to hinder phage therapy and discuss future avenues to explore the full capacity of phage therapy.
Identifiants
pubmed: 32472938
pii: 5849005
doi: 10.1093/femsre/fuaa017
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
684-700Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of FEMS.